Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel with or without prednisone in metastatic castration-resistant prostate cancer after docetaxel
2016-005251-25Phase 2Terminated
- Sponsor
- Consorzio Oncotech
- Start
- Oct 2021
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC), prostate cancer (PCa), sponsored by Consorzio Oncotech. Started Oct 2021; status: terminated.
02
Drugs
cabazitaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)prostate cancer (PCa)
Beyond the preview
Go deeper on 2016-005251-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005251-25.